Latigo Biotherapeutics, Inc. ("Latigo Bio") is a clinical-stage biotechnology company headquartered in Thousand Oaks, California, developing novel non-opioid medicines for acute and chronic pain. Its lead candidates LTG-001 and LTG-321 are oral NaV1.8 sodium-channel inhibitors targeting pain at its peripheral source without the addiction risk of opioids; LTG-001 holds FDA Fast Track designation and reported positive Phase 2b results in post-abdominoplasty acute pain, published in the New England Journal of Medicine in July 2026. The company was founded on human-genetics-validated targets and uses in-house AI/ML and structure-based drug design to optimize potency and selectivity. It debuted in 2024 with a $135M Series A and closed a $150M Series B in March 2025, backed by Westlake Village BioPartners, 5AM Ventures, Foresite Capital and Corner Ventures. Latigo is a therapeutics developer, not a software vendor: it publishes no public API, developer portal, SDK or machine-readable specification.
Latigo Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Drug Discovery.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/latigo-bio: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: latigo-bio
name: Latigo Bio
description: 'Latigo Biotherapeutics, Inc. ("Latigo Bio") is a clinical-stage biotechnology company headquartered in Thousand
Oaks, California, developing novel non-opioid medicines for acute and chronic pain. Its lead candidates LTG-001 and LTG-321
are oral NaV1.8 sodium-channel inhibitors targeting pain at its peripheral source without the addiction risk of opioids;
LTG-001 holds FDA Fast Track designation and reported positive Phase 2b results in post-abdominoplasty acute pain, published
in the New England Journal of Medicine in July 2026. The company was founded on human-genetics-validated targets and uses
in-house AI/ML and structure-based drug design to optimize potency and selectivity. It debuted in 2024 with a $135M Series
A and closed a $150M Series B in March 2025, backed by Westlake Village BioPartners, 5AM Ventures, Foresite Capital and
Corner Ventures. Latigo is a therapeutics developer, not a software vendor: it publishes no public API, developer portal,
SDK or machine-readable specification.'
url: https://raw.githubusercontent.com/api-evangelist/latigo-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-harvest-listing: https://forgeglobal.com/latigo-bio_stock/
x-tier: stub
x-tier-reason: harvest
deliveryModel:
model: saas
open_source: false
commercial: true
callable_host: false
label: Hosted service · you call their endpoint
confidence: medium
source:
- pricing
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
specificationVersion: '0.20'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Discovery
- Clinical Trials
- Healthcare
- Pain Management
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/latigo-bio-domain-security.yml
- type: Website
url: https://latigobio.com/
- type: TermsOfService
url: https://latigobio.com/terms-of-use/
- type: PrivacyPolicy
url: https://latigobio.com/privacy-policy/
x-enrichment:
date: '2026-08-23'
status: minimal
artifacts_added: 2
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: 'Latigo Biotherapeutics is a clinical-stage drug developer whose product is a molecule (oral NaV1.8 inhibitors LTG-001/LTG-321),
not software — it runs no developer program: api., developer., docs., dev., portal., app. and data.latigobio.com are all
NXDOMAIN, github.com/latigobio and /LatigoBiotherapeutics 404, and the corporate site itself sits behind a SiteGround
robot challenge that answers HTTP 202 with an identical challenge shell to every path, including all eight /.well-known/*
probes.'
evidence:
- url: https://latigobio.com/openapi.json
status: 202
- url: https://latigobio.com/.well-known/agent-card.json
status: 202
- url: https://github.com/latigobio
status: 404
- url: https://registry.npmjs.org/latigobio
status: 404
checked: '2026-08-23'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.